Tokyo Tape
Sign in
← Terumo

Quarterly report · Q2

4543.TEDINET S100PLTQ
Period2022-04-01 → 2022-09-30
Filed2022-11-14
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥403.3bn2022-04-01 → 2022-09-30Cons.Revenue IFRS
Revenue¥206.0bn2022-07-01 → 2022-09-30dCons.Revenue IFRS
Revenue¥703.3bn2021-04-01 → 2022-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥344.6bn2021-04-01 → 2021-09-30Cons.Revenue IFRS
Revenue¥172.9bn2021-07-01 → 2021-09-30dCons.Revenue IFRS
Operating income¥56.0bn2022-04-01 → 2022-09-30Cons.Operating profit loss IFRS
Operating income¥25.5bn2022-07-01 → 2022-09-30dCons.Operating profit loss IFRS
Operating income¥65.9bn2021-04-01 → 2021-09-30Cons.Operating profit loss IFRS
Operating income¥29.6bn2021-07-01 → 2021-09-30dCons.Operating profit loss IFRS
Profit before tax¥54.6bn2022-04-01 → 2022-09-30Cons.Profit loss before tax IFRS
Profit before tax¥25.0bn2022-07-01 → 2022-09-30dCons.Profit loss before tax IFRS
Profit before tax¥114.5bn2021-04-01 → 2022-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥65.3bn2021-04-01 → 2021-09-30Cons.Profit loss before tax IFRS
Profit before tax¥29.3bn2021-07-01 → 2021-09-30dCons.Profit loss before tax IFRS
Net income (owners)¥40.3bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥17.9bn2022-07-01 → 2022-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥88.8bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥50.0bn2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥22.1bn2021-07-01 → 2021-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income¥40.3bn2022-04-01 → 2022-09-30Cons.Profit loss IFRS
Net income¥17.9bn2022-07-01 → 2022-09-30dCons.Profit loss IFRS
Net income¥50.0bn2021-04-01 → 2021-09-30Cons.Profit loss IFRS
Net income¥22.1bn2021-07-01 → 2021-09-30dCons.Profit loss IFRS
Total assets¥1.66Tat 2022-09-30Cons.Assets IFRS
Total assets¥1.47Tat 2022-03-31Cons.Assets IFRS
Total assets¥1.37Tat 2021-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥487.8bnat 2022-09-30Cons.Liabilities IFRS
Total liabilities¥461.4bnat 2022-03-31Cons.Liabilities IFRS
Net assets / equity¥1.17Tat 2022-09-30Cons.Equity IFRS
Net assets / equity¥1.01Tat 2022-03-31Cons.Equity IFRS
Net assets / equity¥904.0bnat 2021-09-30Cons.Equity IFRS
Net assets / equity¥856.7bnat 2021-03-31dCons.Equity IFRS
Equity (owners)¥1.17Tat 2022-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.01Tat 2022-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥904.0bnat 2021-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥212.6bnat 2022-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥205.3bnat 2022-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥202.9bnat 2021-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥200.8bnat 2021-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥60.3bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥141.5bn2021-04-01 → 2022-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥66.7bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥31.6bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥78.5bn2021-04-01 → 2022-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥40.5bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥37.9bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥70.9bn2021-04-01 → 2022-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥25.1bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥53.372022-04-01 → 2022-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥23.752022-07-01 → 2022-09-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥117.452021-04-01 → 2022-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥66.112021-04-01 → 2021-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥29.222021-07-01 → 2021-09-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥53.352022-04-01 → 2022-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥23.742022-07-01 → 2022-09-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥117.382021-04-01 → 2022-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥66.072021-04-01 → 2021-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥29.22021-07-01 → 2021-09-30dCons.Diluted earnings loss per share IFRS
Equity ratio70.6%at 2022-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio68.7%at 2022-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio66.0%at 2021-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 20
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue external2022-04-01 → 2022-09-30¥124m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30¥275m
jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segmentrevenue external2022-04-01 → 2022-09-30¥74.0bn
jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segmentsegment profit2022-04-01 → 2022-09-30¥9.1bn
jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segmentrevenue external2022-04-01 → 2022-09-30¥235.4bn
jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segmentsegment profit2022-04-01 → 2022-09-30¥52.9bn
jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segmentrevenue external2022-04-01 → 2022-09-30¥93.8bn
jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segmentsegment profit2022-04-01 → 2022-09-30¥8.1bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥403.2bn
—segment totalsegment profit2022-04-01 → 2022-09-30¥70.2bn
Reconciling Itemsreconcilingrevenue external2021-04-01 → 2021-09-30¥124m
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-09-30−¥1.8bn
jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segmentrevenue external2021-04-01 → 2021-09-30¥58.2bn
jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segmentsegment profit2021-04-01 → 2021-09-30¥11.8bn
jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segmentrevenue external2021-04-01 → 2021-09-30¥194.3bn
jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segmentsegment profit2021-04-01 → 2021-09-30¥50.8bn
jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segmentrevenue external2021-04-01 → 2021-09-30¥92.0bn
jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segmentsegment profit2021-04-01 → 2021-09-30¥13.4bn
—segment totalrevenue external2021-04-01 → 2021-09-30¥344.5bn
—segment totalsegment profit2021-04-01 → 2021-09-30¥76.0bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 696
ItemContextValueUnit
Transfer from other components of equity to retained earnings ss IFRSPrior1YTDDuration－JPY
Share based payment transactions ss IFRSPrior1YTDDuration_ShareCapitalIFRSMember－JPY
Share based payment transactions ss IFRSPrior1YTDDuration_CapitalSurplusIFRSMember10000000JPY
Share based payment transactions ss IFRSPrior1YTDDuration_TreasurySharesIFRSMember91000000JPY
Share based payment transactions ss IFRSPrior1YTDDuration_RetainedEarningsIFRSMember－JPY
Share based payment transactions ss IFRSPrior1YTDDuration_OtherComponentsOfEquityIFRSMember17000000JPY
Share based payment transactions ss IFRSPrior1YTDDuration_EquityAttributableToOwnersOfParentIFRSMember119000000JPY
Share based payment transactions ss IFRSPrior1YTDDuration119000000JPY
Conversion of convertible bonds ss IFRSPrior1YTDDuration_ShareCapitalIFRSMember－JPY
Conversion of convertible bonds ss IFRSPrior1YTDDuration_CapitalSurplusIFRSMember-8000000JPY
Conversion of convertible bonds ss IFRSPrior1YTDDuration_TreasurySharesIFRSMember378000000JPY
Conversion of convertible bonds ss IFRSPrior1YTDDuration_RetainedEarningsIFRSMember－JPY
Conversion of convertible bonds ss IFRSPrior1YTDDuration_OtherComponentsOfEquityIFRSMember－JPY
Conversion of convertible bonds ss IFRSPrior1YTDDuration_EquityAttributableToOwnersOfParentIFRSMember369000000JPY
Conversion of convertible bonds ss IFRSPrior1YTDDuration369000000JPY
Total transactions with owners IFRSPrior1YTDDuration_ShareCapitalIFRSMember－JPY
Total transactions with owners IFRSPrior1YTDDuration_CapitalSurplusIFRSMember-3000000JPY
Total transactions with owners IFRSPrior1YTDDuration_TreasurySharesIFRSMember499000000JPY
Total transactions with owners IFRSPrior1YTDDuration_RetainedEarningsIFRSMember-11324000000JPY
Total transactions with owners IFRSPrior1YTDDuration_OtherComponentsOfEquityIFRSMember-23000000JPY
Total transactions with owners IFRSPrior1YTDDuration_EquityAttributableToOwnersOfParentIFRSMember-10851000000JPY
Total transactions with owners IFRSPrior1YTDDuration-10851000000JPY
Equity IFRSPrior1QuarterInstant_ShareCapitalIFRSMember38716000000JPY
Equity IFRSPrior1QuarterInstant_CapitalSurplusIFRSMember51825000000JPY
Equity IFRSPrior1QuarterInstant_TreasurySharesIFRSMember-6338000000JPY
Equity IFRSPrior1QuarterInstant_RetainedEarningsIFRSMember813741000000JPY
Equity IFRSPrior1QuarterInstant_OtherComponentsOfEquityIFRSMember6011000000JPY
Equity IFRSPrior1QuarterInstant_EquityAttributableToOwnersOfParentIFRSMember903957000000JPY
Equity IFRSPrior1QuarterInstant903957000000JPY
Equity IFRSPrior1YearInstant_ShareCapitalIFRSMember38716000000JPY
Equity IFRSPrior1YearInstant_CapitalSurplusIFRSMember51921000000JPY
Equity IFRSPrior1YearInstant_TreasurySharesIFRSMember-6229000000JPY
Equity IFRSPrior1YearInstant_RetainedEarningsIFRSMember846978000000JPY
Equity IFRSPrior1YearInstant_OtherComponentsOfEquityIFRSMember80926000000JPY
Equity IFRSPrior1YearInstant_EquityAttributableToOwnersOfParentIFRSMember1012313000000JPY
Equity IFRSPrior1YearInstant1012313000000JPY
Profit loss IFRSCurrentYTDDuration_ShareCapitalIFRSMember－JPY
Profit loss IFRSCurrentYTDDuration_CapitalSurplusIFRSMember－JPY
Profit loss IFRSCurrentYTDDuration_TreasurySharesIFRSMember－JPY
Profit loss IFRSCurrentYTDDuration_RetainedEarningsIFRSMember40321000000JPY
Profit loss IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember－JPY
Profit loss IFRSCurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember40321000000JPY
Profit loss IFRSCurrentYTDDuration40321000000JPY
Other comprehensive income IFRSCurrentYTDDuration_ShareCapitalIFRSMember－JPY
Other comprehensive income IFRSCurrentYTDDuration_CapitalSurplusIFRSMember－JPY
Other comprehensive income IFRSCurrentYTDDuration_TreasurySharesIFRSMember－JPY
Other comprehensive income IFRSCurrentYTDDuration_RetainedEarningsIFRSMember－JPY
Other comprehensive income IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember146346000000JPY
Other comprehensive income IFRSCurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember146346000000JPY
Other comprehensive income IFRSCurrentYTDDuration146346000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-09-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-07-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-09-30pass
statement vs summary · revenueconsolidated 2021-07-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2022-07-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass